TODARO, MARIA
TODARO, MARIA
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
2015-01-01 Abate, F.; Todaro, M.; Van Der Krogt, J.-A.; Boi, M.; Landra, I.; Machiorlatti, R.; Tabbò, F.; Messana, K.; Abele, C.; Barreca, A.; Novero, D.; Gaudiano, M.; Aliberti, S.; Di Giacomo, F.; Tousseyn, T.; Lasorsa, E.; Crescenzo, R.; Bessone, L.; Ficarra, E.; Acquaviva, A.; Rinaldi, A.; Ponzoni, M.; Longo, D.L.; Aime, S.; Cheng, M.; Ruggeri, B.; Piccaluga, P.P.; Pileri, S.; Tiacci, E.; Falini, B.; Pera-Gresely, B.; Cerchietti, L.; Iqbal, J.; Chan, W.C.; Shultz, L.D.; Kwee, I.; Piva, R.; Wlodarska, I.; Rabadan, R.; Bertoni, F.; Inghirami, G.
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells
2019-01-01 Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma
2015-01-01 Crescenzo, Ramona; Abate, Francesco; Lasorsa, Elena; Tabbo', Fabrizio; Gaudiano, Marcello; Chiesa, Nicoletta; Di Giacomo, Filomena; Spaccarotella, Elisa; Barbarossa, Luigi; Ercole, Elisabetta; Todaro, Maria; Boi, Michela; Acquaviva, Andrea; Ficarra, Elisa; Novero, Domenico; Rinaldi, Andrea; Tousseyn, Thomas; Rosenwald, Andreas; Kenner, Lukas; Cerroni, Lorenzo; Tzankov, Alexander; Ponzoni, Maurilio; Paulli, Marco; Weisenburger, Dennis; Chan, Wing C.; Iqbal, Javeed; Piris, Miguel A.; Zamo', Alberto; Ciardullo, Carmela; Rossi, Davide; Gaidano, Gianluca; Pileri, Stefano; Tiacci, Enrico; Falini, Brunangelo; Shultz, Leonard D.; Mevellec, Laurence; Vialard, Jorge E.; Piva, Roberto; Bertoni, Francesco; Rabadan, Raul; Inghirami, Giorgio
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells
2020-01-01 Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M.
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target
2016-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, Fr; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
2020-01-01 Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia
2018-01-01 Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Magic pills: new oral drugs to treat chronic lymphocytic leukemia
2017-01-01 Vitale, Candida; Griggio, Valentina; Todaro, Maria; Salvetti, Chiara; Boccadoro, Mario; Coscia, Marta
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.
2013-01-01 Michela Boi; Andrea Rinaldi; Ivo Kwee; Paola Bonetti; Maria Todaro; Fabrizio Tabbò; Roberto Piva; Paola M. V. Rancoita; András Matolcsy; Botond Timar; Thomas Tousseyn; Socorro Maria Rodríguez-Pinilla; Miguel A. Piris; Sílvia Beà; Elias Campo; Govind Bhagat; Steven H. Swerdlow; Andreas Rosenwald; Maurilio Ponzoni; Ken H. Young; Pier Paolo Piccaluga; Reinhard Dummer; Stefano Pileri; Emanuele Zucca; Giorgio Inghirami; Francesco Bertoni
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2018-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2016-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE
2017-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2018-01-01 Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2020-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target
2018-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE
2018-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells
2019-01-01 Vitale, Candida; Todaro, Maria; Griggio, Valentina; Salvetti, Chiara; Riganti, Chiara; Landesman, Yosef; Boccadoro, Mario; Coscia, Marta
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance
2016-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Landesman, Y; Coscia, M
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms
2018-01-01 Circosta, Paola; Elia, Angela Rita; Landra, Indira; Machiorlatti, Rodolfo; Todaro, Maria; Aliberti, Sabrina; Brusa, Davide; Deaglio, Silvia; Chiaretti, Sabina; Bruna, Riccardo; Gottardi, Daniela; Massaia, Massimo; Giacomo, Filomena Di; Guarini, Anna Rita; Foà, Robin; Kyriakides, Peter W.; Bareja, Rohan; Elemento, Olivier; Chichili, Gurunadh R.; Monteleone, Emanuele; Moore, Paul A.; Johnson, Syd; Bonvini, Ezio; Cignetti, Alessandro; Inghirami, Giorgio
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2017-01-01 Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation | 2015 | Abate, F.; Todaro, M.; Van Der Krogt, J.-A.; Boi, M.; Landra, I.; Machiorlatti, R.; Tabbò, F.; Messana, K.; Abele, C.; Barreca, A.; Novero, D.; Gaudiano, M.; Aliberti, S.; Di Giacomo, F.; Tousseyn, T.; Lasorsa, E.; Crescenzo, R.; Bessone, L.; Ficarra, E.; Acquaviva, A.; Rinaldi, A.; Ponzoni, M.; Longo, D.L.; Aime, S.; Cheng, M.; Ruggeri, B.; Piccaluga, P.P.; Pileri, S.; Tiacci, E.; Falini, B.; Pera-Gresely, B.; Cerchietti, L.; Iqbal, J.; Chan, W.C.; Shultz, L.D.; Kwee, I.; Piva, R.; Wlodarska, I.; Rabadan, R.; Bertoni, F.; Inghirami, G. | |
| Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells | 2019 | Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta | |
| Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma | 2015 | Crescenzo, Ramona; Abate, Francesco; Lasorsa, Elena; Tabbo', Fabrizio; Gaudiano, Marcello; Chiesa, Nicoletta; Di Giacomo, Filomena; Spaccarotella, Elisa; Barbarossa, Luigi; Ercole, Elisabetta; Todaro, Maria; Boi, Michela; Acquaviva, Andrea; Ficarra, Elisa; Novero, Domenico; Rinaldi, Andrea; Tousseyn, Thomas; Rosenwald, Andreas; Kenner, Lukas; Cerroni, Lorenzo; Tzankov, Alexander; Ponzoni, Maurilio; Paulli, Marco; Weisenburger, Dennis; Chan, Wing C.; Iqbal, Javeed; Piris, Miguel A.; Zamo', Alberto; Ciardullo, Carmela; Rossi, Davide; Gaidano, Gianluca; Pileri, Stefano; Tiacci, Enrico; Falini, Brunangelo; Shultz, Leonard D.; Mevellec, Laurence; Vialard, Jorge E.; Piva, Roberto; Bertoni, Francesco; Rabadan, Raul; Inghirami, Giorgio | |
| Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells | 2020 | Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M. | |
| HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target | 2016 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, Fr; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
| HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia | 2020 | Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta | |
| Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia | 2018 | Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
| Magic pills: new oral drugs to treat chronic lymphocytic leukemia | 2017 | Vitale, Candida; Griggio, Valentina; Todaro, Maria; Salvetti, Chiara; Boccadoro, Mario; Coscia, Marta | |
| PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. | 2013 | Michela Boi; Andrea Rinaldi; Ivo Kwee; Paola Bonetti; Maria Todaro; Fabrizio Tabbò; Roberto Piva; Paola M. V. Rancoita; András Matolcsy; Botond Timar; Thomas Tousseyn; Socorro Maria Rodríguez-Pinilla; Miguel A. Piris; Sílvia Beà; Elias Campo; Govind Bhagat; Steven H. Swerdlow; Andreas Rosenwald; Maurilio Ponzoni; Ken H. Young; Pier Paolo Piccaluga; Reinhard Dummer; Stefano Pileri; Emanuele Zucca; Giorgio Inghirami; Francesco Bertoni | |
| REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2018 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
| REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2016 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M | |
| REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE | 2017 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
| Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2018 | Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
| Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2020 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
| Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target | 2018 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
| SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE | 2018 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M | |
| Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells | 2019 | Vitale, Candida; Todaro, Maria; Griggio, Valentina; Salvetti, Chiara; Riganti, Chiara; Landesman, Yosef; Boccadoro, Mario; Coscia, Marta | |
| Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance | 2016 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Landesman, Y; Coscia, M | |
| Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms | 2018 | Circosta, Paola; Elia, Angela Rita; Landra, Indira; Machiorlatti, Rodolfo; Todaro, Maria; Aliberti, Sabrina; Brusa, Davide; Deaglio, Silvia; Chiaretti, Sabina; Bruna, Riccardo; Gottardi, Daniela; Massaia, Massimo; Giacomo, Filomena Di; Guarini, Anna Rita; Foà, Robin; Kyriakides, Peter W.; Bareja, Rohan; Elemento, Olivier; Chichili, Gurunadh R.; Monteleone, Emanuele; Moore, Paul A.; Johnson, Syd; Bonvini, Ezio; Cignetti, Alessandro; Inghirami, Giorgio | |
| TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA | 2017 | Vitale, C; Griggio, V; Todaro, M; Riganti, C; Salaroglio, IC; Salvetti, C; Rigoni, M; Foglietta, M; Castella, B; Boccadoro, M; Massaia, M; Coscia, M |